Sydney, Australia, 15 November, 2017: The Directors of Biotron Limited (ASX: BIT) are pleasedto advise that in recently completed preclinical studies several of the Company’s compounds havedemonstrated significant anti-viral activity against hepatitis B (HBV). The studies were completed inthe USA in cell culture models that are considered ‘industry standard’ and are well recognised bypotential pharma and biotech partners.
Myths and Mysteries around BIT and coronavirus, page-4
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
